PRESS RELEASES
November 9, 2020
Decibel Therapeutics Announces $82M Series D Financing to Advance Gene Therapies to Restore Hearing and Balance
November 2, 2020
Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
June 26, 2019
Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors
November 29, 2017
Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus
SELECT POSTERS and PUBLICATIONS
Decibel Corporate Presentation
September 2020
Our CEO, Laurence Reid, Ph.D., presented about Decibel and the company’s programs at Citi’s 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020. The presentation can be found below.
Shuohao, S., Babola, T., Pregernig, G., Bergles, D.E., Burns, J.C. & Mueller, U. (2018). Hair Cell Mechanotransduction Regulates Spontaneous Activity and Spiral Ganglion Subtype Specification in the Auditory System. Cell, 174(5), 1247-1263.
One of the major challenges to realizing the potential of synaptopathy rodent models is that current clinical audiometric approaches cannot yet reveal the presence of this subtle cochlear pathology in humans. This paper frames the key outstanding translational questions that need to be addressed to develop and realize hearing therapeutics.
Hickox, A. E., Larsen, E., Heinz, M. G., Shinobu, L., & Whitton, J. P. (2017). Translational issues in cochlear synaptopathy. Hearing research, 349, 164-171.
Synaptopathy is undetectable by current clinical audiometric measurements in rodent models. This review outlines the key translational questions that need answering to diagnose synaptopathy.
Burns, J. C., & Stone, J. S. (2017). Development and regeneration of vestibular hair cells in mammals. Seminars in cell & developmental biology, 65, 96-105.
Damage to the vestibular system occurs in many different cell types. This review summarizes the current state of knowledge on development, damage, and regeneration of sensory cell types in the mammalian vestibular system and highlights critical information gaps that must be addressed before new therapies for vestibular dysfunction can be defined.